CSL subsidiary strikes agreement with Novartis
18 July, 2002 by Tanya HollisCSL's Swiss subsidiary has struck a deal with drug company Novartis over the marketing and distribution of its intravenous immunoglobulin product.
Ambri appoints business development manager
18 July, 2002 by Tanya HollisBiosensor developer Ambri has appointed a new business development manager to drive sales of its SensiDx System throughout the Asia Pacific region.
Brisbane start-up Protagonist aims for more of a leading role
18 July, 2002 by Pete YoungDrug design start-up Protagonist is attempting to move up the food chain from a tools-oriented company to one with a proprietary interest in the molecules it designs and synthesises.
New Australian group in kidney bioengineering push
17 July, 2002 by Tanya HollisA consortium of Australia's top kidney scientists has come together with the ambitious goal of using stem cells to engineer a bioartificial organ.
New director for Ventracor
17 July, 2002 by Tanya HollisArtificial heart device developer Ventracor has appointed a new director to its ranks.
Peptech looks towards positive second half result in shareholder address
16 July, 2002 by Tanya HollisSydney company Peptech is hinging its hopes for a positive second half result on the issuing of US patents for its anti tumour nectrotising factor.
Interpret GM polls with caution: NZ academic
16 July, 2002 by Tanya HollisPolls claiming to illustrate community views on genetic modification should be interpreted with caution because they did not always take into account a person's knowledge of the topic, a New Zealand academic has warned.
Genesis R&D to study plant hormones
16 July, 2002 by Melissa TrudingerNew Zealand based Genesis Research and Development Corporation will get $NZ6 million from the Foundation for Research Science and Technology to discover and investigate new plant hormones and signalling processes.
Qld teams with US researchers in drought crop project
16 July, 2002 by Melissa TrudingerCollaborative agreements between researchers at the Queensland Department of Primary Industries and three major US universities - Texas A&M University, Texas Tech and the University of Missouri - could lead to development of drought resistant crops.
Get planning, physics head tells synchrotron users
15 July, 2002 by Melissa TrudingerPotential users of Australia's national synchrotron need to start planning now, according to Sir Peter Williams, president of the UK Institute of Physics and proponent of the synchrotron project.
ResMed shrugs off a nervous market
15 July, 2002 by Tanya HollisDespite being regarded as one of Australia's top three listed biotech stocks, sleep disorder specialist ResMed would probably rather forget 2002.
Nasal nerve cells used in spinal repair in world first
12 July, 2002 by Pete YoungThe world's first clinical trial into repairing damaged spinal cords using transplanted nasal nerve cells now underway in Queensland could have global significance.
VosTech's Brightsun acquisition turns up the WA biotech heat
12 July, 2002 by Melissa TrudingerVosTech, a technology investment company based in Perth, is planning to enter the biotechnology market by acquiring animal biotechnology company Brightsun and its associated equity interests in CSIRO spin-off Vectogen and Murdoch University start-up Paragen.
New Zealand feature: election result key to NZ biotech
12 July, 2002 by Tanya HollisWith New Zealand's general election imminent, many in the biotechnology industry believe the outcome could determine the sector's future.
New Zealand feature: primary industry backs NZ biotech
12 July, 2002 by Melissa TrudingerIf biotechnology is as old as agriculture, then biotechnology in New Zealand has been around for as long as the nation. New Zealand is a country that relies on its strengths in its primary industries - dairying and sheep, horticulture and forestry.
